Clinical Trials : Acute Leukemia of Ambiguous Lineage

Recruiting

Study Name: Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Condition:

Acute Biphenotypic Leukemia
de Novo Myelodysplastic Syndrome Date: 2014-01-22
Interventions:
- Drug: Cladribine Given IV

Recruiting

Study Name: Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Condition:

Acute Biphenotypic Leukemia
Adult Acute Lymphoblastic Leukemia
Date: 2008-11-21
Interventions:
- Drug: Cyclosporine Given IV or

Recruiting

Study Name: Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Condition:

Acute Biphenotypic Leukemia
Acute Myeloid Leukemia Arising From
Date: 2008-07-19
Interventions:
- Drug: Cyclophosphamide Given I

Suspended

Study Name: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Condition:

Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Aggres
Date: 2008-07-25
Interventions:
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting

Study Name: HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Condition:

Myelodysplastic Syndrome (MDS)
Chronic Lymphocytic Leukemia (CLL)
Drug: Fludarabine

Completed

Study Name: AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia
Condition: Leukemia
Date: 2011-09-08
Interventions:

Drug: multikinase inhibitor AT9283
Other:

Completed

Study Name: Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
Condition:

Leukemia
Lymphoma
Allogeneic Haematopoietic Stem Cell Tran
Date: 2009-10-02
Interventions:
- Drug: Busulfan Test Dose 32 mg

Not yet recruiting

Study Name: Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
Condition: Hematologic Malignancy
Date: 2016-03-16
Interventions:

Drug: Fludarabine

Completed

Study Name: Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)
Condition: Leukemia
Date: 2014-04-14
Interventions:

Drug: Cladribine

Completed

Study Name: Venetoclax Combined With Azactidine in the Treatment of ALAL
Condition:
Date: 2025-11-04
Interventions: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28);

Search for Clinical Trial Results

Acute Leukemia of Ambiguous Lineage - 21 Studies Found

Status	Study
Recruiting	Study Name: Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Condition: Acute Biphenotypic Leukemia de Novo Myelodysplastic Syndrome Date: 2014-01-22 Interventions: Drug: Cladribine Given IV
Recruiting	Study Name: Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant Condition: Acute Biphenotypic Leukemia Adult Acute Lymphoblastic Leukemia Date: 2008-11-21 Interventions: Drug: Cyclosporine Given IV or
Recruiting	Study Name: Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease Condition: Acute Biphenotypic Leukemia Acute Myeloid Leukemia Arising From Date: 2008-07-19 Interventions: Drug: Cyclophosphamide Given I
Suspended	Study Name: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Condition: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Aggres Date: 2008-07-25 Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Recruiting	Study Name: HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Condition: Myelodysplastic Syndrome (MDS) Chronic Lymphocytic Leukemia (CLL) Drug: Fludarabine
Completed	Study Name: AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia Condition: Leukemia Date: 2011-09-08 Interventions: Drug: multikinase inhibitor AT9283 Other:
Completed	Study Name: Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation Condition: Leukemia Lymphoma Allogeneic Haematopoietic Stem Cell Tran Date: 2009-10-02 Interventions: Drug: Busulfan Test Dose 32 mg
Not yet recruiting	Study Name: Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Condition: Hematologic Malignancy Date: 2016-03-16 Interventions: Drug: Fludarabine
Completed	Study Name: Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) Condition: Leukemia Date: 2014-04-14 Interventions: Drug: Cladribine
Completed	Study Name: Venetoclax Combined With Azactidine in the Treatment of ALAL Condition: Date: 2025-11-04 Interventions: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28);